Neutrophils play an essential role in immune defenses because they ingest, kill, and digest invading microorganisms, including fungi and bacteria. Failure to carry out this role leads to immunodeficiency, which is mainly characterized by the presence of recurrent infections. Defects in neutrophil function can be quantitative, as seen in neutropenia or qualitative, as seen in neutrophil dysfunction. The standard circulating neutrophil count is above 1.5 x 10/L. Neutropenia can be classified in asymptomatic (mild), moderate, and severe, and thus, the progression to infection concerning the number.
Neutropenia, with decreased production with marrow hypoplasia, can be primary and due to chronic benign neutropenia, cyclical neutropenia, and other congenital and familial neutropenias. It can be secondary to cytotoxic drugs, aplastic anemia, leukemia, drug reactions, and infections. Neutropenia, with increased destruction with marrow hyperplasia, is due to hypersplenism and immune neutropenia. Secondary causes are the commonest. For example, neutropenia caused as a side effect of chemotherapy for malignancies. Congenital forms are rare and vary in severity; some of them are life-threatening conditions including leukocyte adhesion deficiency, Chediak-Higashi syndrome, hyper-IgE, recurrent infection syndrome, and chronic granulomatous disease.
Low levels of neutrophils may be due to hypoplastic bone marrow, an infection, radiation exposure, tumor infiltration of the bone marrow, myelofibrosis, prolonged exposure to a drug, or a hereditary disorder. Congenital neutropenia or Kostmann syndrome is acquired in an autosomal recessive fashion.
Drugs known to cause neutropenia include:
Antineutrophil or autoimmune neutropenia has been observed in:
Almost any infection can cause neutropenia. The condition is also seen with folate, vitamin B12, and copper deficiency.
Hsieh and collaborators reported that in the United States, the prevalence of neutropenia was 0.38% among Mexican-Americans, 0.79% among whites, and 4.5% among black participants. Weycker and collaborators reported that the risk of febrile neutropenia during the chemotherapy regimen course for treating solid tumor was 16.8%. Severe neutropenia was present in 1 of every 2 patients with lymphoma receiving chemotherapy with a higher risk of febrile neutropenia, and it was found in approximately 1 of every 10 breast cancer patients in Spain.
Neutrophils play a role in the immune defense against extracellular bacteria, including Staphylococci, Streptococci, and Escherichia coli, among others. They also protect against fungal infections, including those produced by Candida albicans. Once their count is below 1 x 10/L recurrent infections start. As compensation, the monocyte count may increase. In primary neutropenia disorders such as chronic granulomatous disease presents with recurrent infections affecting many organs since childhood. It is caused from a failure to produce toxic reactive oxygen species so that the neutrophils can ingest the microorganisms, but they are unable to kill them, as a significant consequence granuloma can obstruct organs such as the stomach, esophagus, or bladder. Patients with this disease are very susceptible to opportunistic infections by certain bacteria and fungi, especially with Serratia and Burkholderia.
Leukocyte adhesion deficiency has an autosomal recessive inheritance, and its functional defect is a failure of neutrophils to adhere to endothelial cells and so to traverse into tissues to ingest and kill bacteria. Chediak-Higashi syndrome is also an autosomal recessive problem, characterized by abnormal chemotaxis, so neutrophils fail to reach bacteria, and reduced microbicidal activity as lysosomes fail to fuse with phagosomes.
In Chediak-Higashi syndrome, histologically present with giant lysosomal granules in secretory cells. The chronic granulomatous disease is characterized by the presence of granulomas, which are composed of histiocytes that can fuse to form multinucleated giant cells and might be surrounded by other immune cells such as lymphocytes and cover with collagen.
Quantitative Serum Immunoglobulins
Blood Lymphocyte Subpopulations
Nitroblue tetrazolium (NBT) test (before and after stimulation with endotoxin)
Complement System Evaluation
Measurement of individuals components by immunoprecipitation tests, ELISA, or Western blotting
Complement system functional studies
Other investigations of immunodeficiency disorders
Application of granulocyte-colony stimulating factor (G-CSF) can improve neutrophil functions and number. Prophylactic use of antibiotics and antifungals is reserved for some forms of alteration in neutrophil function such as chronic granulomatous disease CGD). The utilization of antimicrobials is compulsory if recurrent infections exist. Interferon-gamma has been successfully used to improve the quality of life of the patient suffering from neutropenia. Allogenic bone marrow transplantation from an HLA-matched related donor can cure CGD but has a high mortality rate , and gene therapy is also a therapeutic option for treating disorders with neutropenia. Furthermore, intravenous immunoglobulins can be another option in the management of these disorders.
Neutropenia can differentiate from antibody deficiency disorders, where a class or different classes of immunoglobulins are below the normal range or absence. These disorders may present clinically by recurrent infections with bacteria and fungi; some of them are opportunistic pathogens, so the use of antimicrobials to treat infectious diseases is a norm. A patient with neutropenia may have an intact acquired immune response but a low number or impaired function of neutrophils. Some complement system deficiency, e.g., C3 deficiency manifests with multiple extracellular bacterial infections and may resemble neutropenia, but can rule out by quantification and functional assessment of the complement system.
The prognosis of neutropenia disorders depends on the cause and organs involved. CGD has a better prognosis if allogeneic bone marrow transplantation can successfully achieve. Neutropenia due to chemotherapy or drugs may cause remission once the treatment is over. Some primary defects of neutrophil functions affect the prognosis, where devastating fatal diseases can lead to death at a young age.
Serious infections occur in a significant number of patients with neutropenia, and many require repeated admissions. Without treatment, neutropenia is associated with a high risk of death.
Neutropenia is a serious life-threatening disorder with high morbidity and mortality. Thus the condition is best managed by an interprofessional team that includes physicians, nurses, and pharmacists. A specialist in infectious diseases, internal medicine specialists, or pediatricians should recommend treatment options, including antibiotics and antifungal. A patient with severe neutropenia is considered to have a life-threatening disorder and should be monitored regularly for complete blood cell count, blood chemistry, infectious disease markers, and immunotherapy. Nurses looking after these patients should know what signs and symptoms to monitor for and when to call the specialist. They educate the patient about precautions and warning signs. Pharmacists review the prescription for dose, contraindications, and interactions. They, too, provide patient education.
Further, these patients should avoid exposure to people and wear a face mask in public. The pharmacist should assess the medications and immediately recommend discontinuation of those associated with neutropenia. Those who are undergoing chemotherapy should be educated about handwashing and symptoms to watch for.
The use of neutrophil colony-stimulating factors should be monitored by an immunologist or hematologist to treat the side effects of this cytokine efficiently.
Only through such a team approach can the morbidity of neutropenia be lowered. [Level 5]
|||Immunodeficiency, Justiz Vaillant AA,Qurie A,,, 2018 Jan [PubMed PMID: 29763203]|
|||Neutropenia and primary immunodeficiency diseases., Rezaei N,Moazzami K,Aghamohammadi A,Klein C,, International reviews of immunology, 2009 [PubMed PMID: 19811314]|
|||Severe congenital neutropenia: new genes explain an old disease., Bohn G,Welte K,Klein C,, Current opinion in rheumatology, 2007 Nov [PubMed PMID: 17917547]|
|||Accelerated phase of chediak higashi syndrome mimicking lymphoma--a case report., Nargund AR,Madhumathi DS,Premalatha CS,Rao CR,Appaji L,Lakshmidevi V,, Journal of pediatric hematology/oncology, 2010 Aug [PubMed PMID: 20661157]|
|||Prevalence of neutropenia in the U.S. population: age, sex, smoking status, and ethnic differences., Hsieh MM,Everhart JE,Byrd-Holt DD,Tisdale JF,Rodgers GP,, Annals of internal medicine, 2007 Apr 3 [PubMed PMID: 17404350]|
|||Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings., Weycker D,Barron R,Kartashov A,Legg J,Lyman GH,, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2014 Jun [PubMed PMID: 23824496]|
|||Incidence of chemotherapy-induced neutropenia and current practice of prophylaxis with granulocyte colony-stimulating factors in cancer patients in Spain: a prospective, observational study., Jolis L,Carabantes F,Pernas S,Cantos B,López A,Torres P,Funes C,Caballero D,Benedit P,Salar A,, European journal of cancer care, 2013 Jul [PubMed PMID: 23730920]|
|||Chronic Granulomatous Disease: Epidemiology, Pathophysiology, and Genetic Basis of Disease., Rider NL,Jameson MB,Creech CB,, Journal of the Pediatric Infectious Diseases Society, 2018 May 9 [PubMed PMID: 29746675]|
|||Chediak-Higashi syndrome: four cases from Northern Finland., Möttönen M,Lanning M,Baumann P,Saarinen-Pihkala UM,, Acta paediatrica (Oslo, Norway : 1992), 2003 Sep [PubMed PMID: 14599068]|
|||Evaluation of a Risk-guided Strategy for Empiric Carbapenem Use in Febrile Neutropenia., Khoo AL,Zhao YJ,Teng M,Ying D,Jin J,Chee YL,Poon LM,Lim SE,Koh LP,Chng WJ,Lim BP,Hsu LY,Ann Chai LY,, International journal of antimicrobial agents, 2018 May 8 [PubMed PMID: 29751120]|
|||Clinical, laboratory and molecular signs of immunodeficiency in patients with partial oculo-cutaneous albinism., Dotta L,Parolini S,Prandini A,Tabellini G,Antolini M,Kingsmore SF,Badolato R,, Orphanet journal of rare diseases, 2013 Oct 17 [PubMed PMID: 24134793]|
|||Clinical manifestations and outcomes of pediatric chronic neutropenia., Wan C,Yu HH,Lu MY,Lee JH,Wang LC,Lin YT,Yang YH,Chiang BL,, Journal of the Formosan Medical Association = Taiwan yi zhi, 2012 Apr [PubMed PMID: 22526211]|
|||Prevention of Infectious Complications in Patients With Chronic Granulomatous Disease., Slack MA,Thomsen IP,, Journal of the Pediatric Infectious Diseases Society, 2018 May 9 [PubMed PMID: 29746681]|
|||Skin manifestations in primary immunodeficient children., Al-Herz W,Nanda A,, Pediatric dermatology, 2011 Sep-Oct [PubMed PMID: 21453308]|
|||Zermatten MG,Koenig C,von Allmen A,Agyeman P,Ammann RA, Episodes of fever in neutropenia in pediatric patients with cancer in Bern, Switzerland, 1993-2012. Scientific data. 2019 Jan 15; [PubMed PMID: 30644854]|
|||Wuyts L,Wojciechowski M,Maes P,Matthieu L,Lambert J,Aerts O, Juvenile ecthyma gangrenosum caused by Pseudomonas aeruginosa revealing an underlying neutropenia: case report and review of the literature. Journal of the European Academy of Dermatology and Venereology : JEADV. 2019 Jan 11; [PubMed PMID: 30633375]|
|||Myeloid-derived suppressor cells (MDSCs) in patients with solid tumors: considerations for granulocyte colony-stimulating factor treatment., Pilatova K,Bencsikova B,Demlova R,Valik D,Zdrazilova-Dubska L,, Cancer immunology, immunotherapy : CII, 2018 May 10 [PubMed PMID: 29748897]|
|||Efficacy of recombinant human granulocyte-colony stimulating factor alone and in combination with antifungal agents against disseminated trichosporonosis in neutropenic mice., Perparim K,Hashimoto A,Nasu M,, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 1996 [PubMed PMID: 29681373]|
|||Allogeneic Hematopoietic Cell Transplantation for Chronic Granulomatous Disease: Controversies and State of the Art., Connelly JA,Marsh R,Parikh S,Talano JA,, Journal of the Pediatric Infectious Diseases Society, 2018 May 9 [PubMed PMID: 29746680]|
|||Justiz Vaillant AA,Ramphul K, Antibody Deficiency Disorder 2018 Jan; [PubMed PMID: 29939682]|
|||Afzali P,Isaeian A,Sadeghi P,Moazzami B,Parvaneh N,Robatjazi M,Ziaee V, Complement deficiency in pediatric-onset systemic lupus erythematosus. Journal of laboratory physicians. 2018 Apr-Jun; [PubMed PMID: 29692593]|
|||García de Guadiana-Romualdo L,Cerezuela-Fuentes P,Español-Morales I,Esteban-Torrella P,Jiménez-Santos E,Hernando-Holgado A,Albaladejo-Otón MD, Prognostic value of procalcitonin and lipopolysaccharide binding protein in cancer patients with chemotherapy-associated febrile neutropenia presenting to an emergency department. Biochemia medica. 2019 Feb 15; [PubMed PMID: 30591812]|